ATAI is concentrating its efforts on psychedelics biotech, with BPL-003 as its main asset targeting treatment-resistant depression (TRD). The company has aligned BPL-003's research with FDA feedback and plans to start two Phase 3 trials, expecting topline results by early 2029. Other pipeline assets like VLS-01 and EMP-01 offer additional catalysts and potential in social anxiety disorders. Despite a premium valuation, ATAI's focus on large market opportunities in mental health makes it a compelling investment prospect.
ZenaTech announced an annualized revenue run rate of approximately CAD 33 million for 2026, based on Q1 2026 revenue of CAD 8.3 million multiplied by four. This growth reflects the integration of recent Drone as a Service (DaaS) acquisitions and ongo...
Aduro Clean Technologies and AstroTurf have signed a memorandum of understanding to evaluate Aduro's Hydrochemolytic™ Technology (HCT) for recycling polyethylene (PE) and polypropylene (PP) from synthetic turf at the end of its life. This collaborati...
Aduro Clean Technologies and AstroTurf have signed a memorandum of understanding to evaluate Aduro's Hydrochemolytic™ technology for recycling end-of-life synthetic turf. This collaboration aims to recover polyethylene (PE) and polypropylene (PP) fro...
XPeng Inc. delivered 40,126 vehicles in June 2026, totaling 103,295 vehicles for the second quarter. The company also marked a milestone with 10,000 units of its GX model produced. XPeng plans to launch the new XPENG MONA L03 in China on July 2, 2026...
NIO Inc. reported delivering 40,597 vehicles in June 2026, marking a 62.9% increase year-over-year. For the second quarter, deliveries reached 107,658 vehicles, up 49.4% compared to the same period last year, bringing total cumulative deliveries to 1...
